Clearance of influenza virus infections by T cells: Risk of collateral damage?

Current Opinion in Virology

Volumn 3, Issue 4, 2013, Pages 430-437

  Hillaire, M L B ^a   Rimmelzwaan, G F ^a   Kreijtz, J H C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE;

ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; LUNG INJURY; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS INFECTION;

EID: 84885034684     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.05.002     Document Type: Review

References (97)

1. Smith DJ et al.: Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305(5682):371-376. (Pubitemid 38938148)
2. DawoodFSetal.:Estimatedglobalmortalityassociatedwiththefirst 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect Dis 2012, 12(9):687-695.
3. Neumann G, Noda T, Kawaoka Y: Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459(7249):931-939.
4. Hillaire ML, Osterhaus AD, Rimmelzwaan GF: Induction of virusspecific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011:p939860.
5. Rimmelzwaan GF, Fouchier RA, Osterhaus AD: Influenza virusspecific cytotoxic T lymphocytes: Acorrelate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007, 18(6):529-536.
6. Damjanovic D et al.: Immunopathology in influenza virus infection: uncoupling the friend from foe. Clin Immunol 2012, 144(1):57-69.
7. Wells MA, Albrecht P, Ennis FA: Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and Tdeficient mice. J Immunol 1981, 126(3):1036-1041. (Pubitemid 11155751)
8. Small BA et al.: CD8(+) T cell-mediated injury in vivo progresses in the absence of effector T cells. J Exp Med 2001, 194(12):1835-1846. (Pubitemid 34028662)
9. Enelow RI et al.: Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998, 102(9):1653-1661. (Pubitemid 28516250)
10. Wiley JA et al.: Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol 2001, 158(1):119-130. (Pubitemid 32096477)
11. van Riel D et al.: H5N1 virus attachment to lower respiratory tract. Science 2006, 312(5772):p399.
12. van Riel D et al.: Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses. Am J Pathol 2010, 176(4):1614-1618.
13. van Stipdonk MJ, Lemmens EE, Schoenberger SP: Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001, 2(5):423-429. (Pubitemid 33706140)
14. van Stipdonk MJ et al.: Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 2003, 4(4):361-365.
15. Wong P, Pamer EG: Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion. J Immunol 2004, 172(4):2171-2176. (Pubitemid 38182363)
16. Peperzak V et al.: CD27 sustains survival of CTLs in virusinfected nonlymphoid tissue in mice by inducing autocrine IL- 2 production. J Clin Invest 2010, 120(1):168-178.
17. Plumb AW et al.: Interleukin-7, but not thymic stromal lymphopoietin, plays a key role in the T cell response to influenza a virus. PLoS ONE 2012, 7(11):pe50199.
18. Seah SG et al.: Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response. J Leukoc Biol 2012, 93(1):145-154.
19. Seah SG et al.: Unlike CD4+ T-cell help, CD28 costimulation is necessary for effective primary CD8+ T-cell influenza-specific immunity. Eur J Immunol 2012, 42(7):1744-1754.
20. Verbist KC et al.: A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection. J Immunol 2011, 186(1):174-182.
21. La Gruta NL et al.: A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007, 85(2):85-92.
22. Snell LM et al.: CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol 2010, 185(12):7223-7234.
23. Dolfi DV et al.: Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol 2011, 186(8):4599- 4608.
24. Morimoto J et al.: Osteopontin modulates the generation of memory CD8+ T cells during influenza virus infection. J Immunol 2011, 187(11):5671-5683.
25. Wensveen FM et al.: Pro-apoptotic protein noxa regulates memory T cell population size and protects against lethal immunopathology. J Immunol 2012, 190(3):1180-1191.
26. Kohlmeier JE et al.: Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J Exp Med 2011, 208(8):1621-1634.
27. Shen CH et al.: Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues. Proc Natl Acad Sci USA 2010, 107(52):22587-22592.
28. Luciani F et al.: Increasing viral dose causes a reversal in CD8+ T cell immunodominance during primary influenza infection due to differences in antigen presentation, T cell avidity, and precursor numbers. J Immunol 2013, 190(1):36-47.
29. Takamura S et al.: The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen. J Exp Med 2010, 207(6):1153-1160.
30. Lee YT et al.: Environmental and antigen receptor-derived signals support sustained surveillance of the lungs by pathogen-specific cytotoxic T lymphocytes. J Virol 2011, 85(9):4085-4094.
31. Kim TS et al.: Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med 2010, 207(6):1161-1172.
32. McMichael AJ et al.: Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309(1):13-17. (Pubitemid 13062888)
33. McMichael AJ et al.: Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986, 67(Pt 4):719-726. (Pubitemid 16048050)
34. Townsend AR, Skehel JJ: The influenza A virus nucleoprotein gene controls the induction of both subtype specific and crossreactive cytotoxic T cells. J Exp Med 1984, 160(2):552-563. (Pubitemid 14052516)
35. Gotch F et al.: Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987, 165(2):408-416. (Pubitemid 17019824)
36. Yewdell JW et al.: Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985, 82(6):1785-1789. (Pubitemid 15085262)
37. Ho AW et al.: Lung CD103+ dendritic cells efficiently transport influenza virus to the lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells. J Immunol 2011, 187(11):. 6011-6021.
38. Hillaire ML et al.: Characterization of the human CD8(+) T cell response following infection with 2009 pandemic influenza H1N1 virus. J Virol 2011, 85(22):12057-12061.
39. Hamada H et al.: Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection. J Immunol 2013, 190(1):296-306.
40. Zhong W et al.: Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections. PLoS ONE 2010, 5(5):pe10583.
41. O'Neill E et al.: Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 2000, 81(Pt 11):2689-2696.
42. Bodewes R et al.: Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 2009, 4(5):pe5538.
43. Kreijtz JH et al.: Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007, 25(4): 612-620. (Pubitemid 44856111)
44. Bodewes R et al.: Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 2011, 85(6):2695-2702.
45. Kreijtz JH et al.: Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009, 27(36):4983-4989.
46. Nguyen HH et al.: Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosaassociated tissues. Virology 1999, 254(1):50-60. (Pubitemid 29391713)
47. Schulman JL, Kilbourne ED: Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J Bacteriol 1965, 89:170-174.
48. Seo SH, Webster RG: Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001, 75(6):2516-2525. (Pubitemid 32185015)
49. Yap KL, Ada GL, McKenzie IF: Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273(5659):238-239. (Pubitemid 8331715)
50. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF: Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin 2009, 5(3):126-135.
51. Grebe KM, Yewdell JW, Bennink JR: Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 2008, 10(9):1024-1029.
52. Hancock K et al.: Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
53. Ge X et al.: Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010, 84(7):3312-3319.
54. Schmidt T et al.: CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur J Immunol 2012, 42(7):1755-1766.
55. Alam S, Sant AJ: Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol 2011, 85(24):13310-13321.
56. Schanen BC et al.: Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011, 29(17):3299- 3309.
57. Duvvuri VR et al.: Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza Other Respir Viruses 2010, 4(5):249-258.
58. Hillaire ML et al.: Human T cells directed to seasonal influenza A virus cross-react with A(H1N1)pdm09 and swine origin triple reassortant H3N2 influenza viruses. J Gen Virol 2012, 94(Pt 3): 583-592.
59. Tu W et al.: Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010, 84(13):6527-6535.
60. Weinfurter JT et al.: Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011, 7(11):pe1002381.
61. Gras S et al.: Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci USA 2010, 107(28):12599-12604.
62. Hillaire ML et al.: Cross-protective immunity to influenza pH1N1 2009 viruses induced by seasonal A(H3N2) virus is mediated by virus-specific T cells. J Gen Virol 2011, 92(Pt 10):2339-2349.
63. Greenbaum JA et al.: Pre-existing immunity against swineorigin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009, 106(48):20365-20370.
64. Wilkinson TM et al.: Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18(2):274-280.
65. Piet B et al.: CD8(+) T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest 2011, 121(6):2254-2263.
66. Jennrich S et al.: Tissue exit: A novel control point in the accumulation of antigen-specific CD8 T cells in the influenza a virus-infected lung. J Virol 2012, 86(7):3436-3445.
67. Ng WF et al.: Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells. Blood 2001, 98(9):2736-2744.
68. O'Garra A, Vieira P: Regulatory T cells and mechanisms of immune system control. Nat Med 2004, 10(8):801-805. (Pubitemid 39070850)
69. Shevach EM: CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002, 2(6):389-400. (Pubitemid 37328746)
70. Piersma SJ et al.: Influenza matrix 1-specific human CD4+ FOXP3+ and FOXP3(S) regulatory T cells can be detected long after viral clearance. Eur J Immunol 2010, 40(11):3064-3074.
71. Chappert P et al.: Antigen-specific Treg impair CD8(+) T-cell priming by blocking early T-cell expansion. Eur J Immunol 2010, 40(2):339-350.
72. Brincks EL et al.: Antigen-specific memory regulatory CD4+Foxp3+ T cells control memory responses to influenza virus infection. J Immunol 2013, 190(7):3438-3446.
73. Paget C et al.: Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. J Immunol 2011, 186(10):5590-5602.
74. Ito T et al.: The critical role of Notch ligand Delta-like 1 in the pathogenesis of influenza A virus (H1N1) infection. PLoS Pathog 2011, 7(11):pe1002341.
75. Hufford MM et al.: Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J Exp Med 2011, 208(y): 167-180.
76. Sharma S et al.: T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virusspecific humoral and CD8 T-cell responses. Proc Natl Acad Sci USA 2011, 108(47):19001-19006.
77. Rygiel TP et al.: Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol 2009, 183(3):1990-1996.
78. Wensveen FM et al.: CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load. J Immunol 2012, 188(9):4256-4267.
79. Sun J et al.: Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009, 15(3):277-284. This study describes how effector T cells are able to control lung inflammation by producing IL-10 simultaneously with pro-inflammatory cytokines.
80. Langlois RA, Legge KL: Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells. J Immunol 2010, 184(8):4440-4446.
81. Zhao MQ et al.: Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition. J Clin Invest 2000, 106(6):R49-R58.
82. Liu AN et al.: Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Am J Respir Cell Mol Biol 1999, 20(5):849-858. (Pubitemid 129540842)
83. Srikiatkhachorn A et al.: Interference with intraepithelial TNFalpha signaling inhibits CD8(+) T-cell-mediated lung injury in influenza infection. Viral Immunol 2010, 23(6):639-645. By interfering with TNFa signalling the authors were able to modulate CD8-mediated inflammation in the lungs of influenza virus-infected mice. This excellent study provides insights in the role of T cells in immunopathology during influenza virus infection.
84. Zhou J et al.: Cutting edge: engagement of NKG2A on CD8+ effector T cells limits immunopathology in influenza pneumonia. J Immunol 2008, 180(1):25-29.
85. Humphreys IR et al.: A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 2003, 198(8):1237-1242. (Pubitemid 37323388)
86. Kim JE et al.: CD4+/CD8+ T lymphocytes imbalance in children with severe 2009 pandemic influenza A (H1N1) pneumonia. Korean J Pediatr 2011, 54(5):207-211. The authors isolated PBMC from hospitalized children suffering from severe A(H1N1)pdm09 virus pneumonia and demonstrated that an elevated CD8 T cell count correlated with severity of disease.
87. Teijaro JR et al.: Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus. J Immunol 2009, 182(11):6834-6843. In this manuscript the authors used a CD28 antagonist to prevent the development of immunopathology by influenza virus-specific memory T cells.
88. Antunes I, Kassiotis G: Suppresion of innate immune pathology by regulatory T cells during influenza A infection of immunodeficient mice. J Virol 2010, 84:12564-12575.
89. Zhao Y et al.: High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. Am J Respir Crit Care Med 2012, 186(12):1292-1297.
90. Guo X et al.: Dynamic variations in the peripheral blood lymphocyte subgroups of patients with 2009 pandemic H1N1 swine-origin influenza A virus infection. Virol J 2011, 8:p215.
91. Khoufache K et al.: PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest 2013, 123(1):206-214.
92. Khoufache K et al.: Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFNgamma- dependent pathway. J Immunol 2009, 182(12): 7795-7802.
93. LeBouder F et al.: Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin. J Virol 2008, 82(14): 6820-6828. (Pubitemid 351977703)
94. Lebouder F et al.: Plasminogen promotes influenza A virus replication through an annexin II-dependent pathway in absence of neuraminidase. J Gen Virol 2010, 91(Pt 11): 2753-2761.
95. Kuiken T et al.: Pathogenesis of influenza virus infections: The good, the bad and the ugly. Curr Opin Virol 2012, 2(3):276-286.
96. Kim TS, Sun J, Braciale TJ: T cell responses during influenza infection: getting and keeping control. Trends Immunol 2011, 32(5):225-231.
97. Braciale TJ, Sun J, Kim TS: Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol 2012, 12(4):295-305.